rofecoxib has been researched along with Dyspepsia in 7 studies
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare patient and physician attitudes to osteoarthritis (OA) treatment with rofecoxib or traditional non-steroidal anti-inflammatory drugs (tNSAIDs)." | 9.10 | Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. ( Aragón, B; Arboleya, LR; de la Figuera, E; Soledad García, M, 2003) |
| " To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs." | 8.80 | Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. ( Bolognese, JA; Harper, SE; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 2000) |
| "To compare patient and physician attitudes to osteoarthritis (OA) treatment with rofecoxib or traditional non-steroidal anti-inflammatory drugs (tNSAIDs)." | 5.10 | Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. ( Aragón, B; Arboleya, LR; de la Figuera, E; Soledad García, M, 2003) |
| " To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs." | 4.80 | Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. ( Bolognese, JA; Harper, SE; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 2000) |
| " Dyspepsia and nausea were the most frequently reported adverse events." | 1.32 | Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. ( Layton, D; Riley, J; Shakir, SA; Wilton, LV, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van der Bijl, P | 2 |
| Layton, D | 1 |
| Riley, J | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Arboleya, LR | 1 |
| de la Figuera, E | 1 |
| Soledad García, M | 1 |
| Aragón, B | 1 |
| Celik, JB | 1 |
| Tuncer, S | 1 |
| Reisli, R | 1 |
| Sarkilar, G | 1 |
| Celik, C | 1 |
| Akyürek, C | 1 |
| Hollenz, M | 1 |
| Labenz, J | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
2 reviews available for rofecoxib and Dyspepsia
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Dy | 2002 |
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Tr | 2000 |
2 trials available for rofecoxib and Dyspepsia
| Article | Year |
|---|---|
Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dyspeps | 2003 |
A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy.
Topics: Adult; Analgesia; Cyclooxygenase Inhibitors; Dyspepsia; Female; Gastrointestinal Diseases; Heartburn | 2003 |
3 other studies available for rofecoxib and Dyspepsia
| Article | Year |
|---|---|
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inh | 2003 |
[Gastrointestinal complications under NSAID treatment in the doctor's office].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Dicl | 2004 |
Rofecoxib for osteoarthritis and pain.
Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit | 1999 |